Jackson Thornton Wealth Management LLC Takes Position in Regeneron Pharmaceuticals, Inc. $REGN

Jackson Thornton Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 921 shares of the biopharmaceutical company’s stock, valued at approximately $519,000.

Several other large investors also recently added to or reduced their stakes in the business. State Street Corp raised its holdings in shares of Regeneron Pharmaceuticals by 0.9% during the 2nd quarter. State Street Corp now owns 4,832,002 shares of the biopharmaceutical company’s stock valued at $2,536,801,000 after buying an additional 42,343 shares in the last quarter. Dodge & Cox lifted its stake in Regeneron Pharmaceuticals by 64.6% in the second quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock worth $2,008,799,000 after acquiring an additional 1,502,198 shares during the period. Franklin Resources Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 1.6% during the 2nd quarter. Franklin Resources Inc. now owns 2,313,496 shares of the biopharmaceutical company’s stock valued at $1,214,585,000 after purchasing an additional 36,821 shares in the last quarter. Loomis Sayles & Co. L P lifted its holdings in Regeneron Pharmaceuticals by 18.6% in the second quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock worth $1,019,062,000 after buying an additional 305,089 shares during the period. Finally, Norges Bank bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $628,151,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $720.00 on Tuesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.33 and a current ratio of 4.06. The company has a market capitalization of $75.67 billion, a PE ratio of 17.41, a P/E/G ratio of 1.92 and a beta of 0.39. The company has a 50-day simple moving average of $750.43 and a two-hundred day simple moving average of $638.67. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The company had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. During the same quarter in the previous year, the firm earned $12.46 EPS. Regeneron Pharmaceuticals’s revenue was up .9% compared to the same quarter last year. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Thursday, November 20th were paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.5%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is currently 8.43%.

Insiders Place Their Bets

In other news, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the sale, the vice president directly owned 4,233 shares in the company, valued at $2,757,503.19. This trade represents a 9.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Christine A. Poon sold 6,500 shares of the company’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the transaction, the director directly owned 2,352 shares of the company’s stock, valued at $1,538,843.04. The trade was a 73.43% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 8,431 shares of company stock worth $5,733,521. Company insiders own 7.02% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on REGN. Truist Financial boosted their target price on shares of Regeneron Pharmaceuticals from $798.00 to $820.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Hsbc Global Res raised Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 24th. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Cantor Fitzgerald upped their target price on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. Finally, Bank of America upgraded shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and lifted their price target for the company from $627.00 to $860.00 in a report on Wednesday, January 7th. Four equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $791.05.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.